Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).
Weimin Li
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Joyce O'Shaughnessy
Honoraria - Johnson & Johnson
Deborah Sokol Ricci
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Thomas W. Griffin
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Thian San Kheoh
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Margaret K. Yu
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Michael Gormley
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Jason L. Martin
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Michael Schaffer
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Kathy Zelinsky
Employment or Leadership Position - Janssen Research & Development
Daniel F. Hayes
Stock Ownership - Inbiomotion; MedImmune
Research Funding - Janssen Diagnostics
Mario Campone
Consultant or Advisory Role - Novartis/Servier
Honoraria - Novartis/Servier
Igor Bondarenko
No relevant relationships to disclose
Irina Zbarskaya
No relevant relationships to disclose
Etienne Brain
No relevant relationships to disclose
Marina B. Stenina
No relevant relationships to disclose
Olga Ivanova
No relevant relationships to disclose
Marie-Pascale Graas
No relevant relationships to disclose
Patrick Neven
No relevant relationships to disclose
Stephen R. D. Johnston
No relevant relationships to disclose